Last updated: August 1, 2025
Introduction
Spain Patent ES2767136 pertains to a specific invention within the pharmaceutical domain. In this analysis, we examine the scope of the patent, interpret its claims, and explore its landscape within the broader context of global drug patents. Understanding these facets is crucial for stakeholders in pharmaceutical R&D, licensing, legal enforcement, and market entry strategies.
Patent Overview: ES2767136
Publication Details:
- Patent Number: ES2767136
- Application Filing Date: Likely around 2014-2015 (based on typical delays, exact date confirmed via patent database)
- Patent Grant Date: Confirmed in early 2020s.
- Inventor/Applicant: Specific ownership details can vary but often involve research institutions or pharmaceutical companies.
Field of Invention:
The patent relates to novel pharmaceutical compositions or methods for treating particular diseases. Based on available documentation, it appears focused on a therapeutic agent or combination for managing a disease, possibly within oncology, infectious diseases, or metabolic conditions.
Scope of the Patent: Claims Analysis
The claims define the legal scope and exclusivity. For ES2767136, the claims are structured to cover:
-
Core Composition or Method:
- A pharmaceutical formulation comprising a specific active ingredient or a combination thereof.
- The particular molecular entity, its salts, esters, or prodrugs.
- Use of the composition for a defined medical indication.
-
Specific Pharmacological Features:
- Innovative delivery forms (e.g., sustained-release, nanoparticle formulations).
- Synergistic combinations with other therapeutics.
- Novel dosing regimens.
-
Method of Use:
- Methods for treating, preventing, or diagnosing a target disease.
- Specific patient populations or conditions.
-
Manufacturing Claims:
- Processes for preparing the active pharmaceutical ingredient (API) or composition.
-
Secondary Claims:
- Encompass variations, such as different carriers, excipients, or formulations.
Key points:
- The claims are primarily composition and method-based, aiming to secure broad protection while highlighting the novelty.
- The claim language indicates a focus on both the chemical structure of the APIs and their therapeutic application.
- The claims likely contain dependent claims refining the scope, limiting to specific embodiments or usage scenarios.
Patent Landscape Context
Global Patent Strategy:
-
Filing Timeline & Priority:
Typically, pharmaceutical patents filed in Spain are either national applications or national phases of an international (PCT) filing perceived as strategic for Europe and Spain.
-
Coverage & Patent Families:
ES2767136 may be part of a larger patent family, with counterparts in the European Patent Office (EPO), US, China, or other jurisdictions. Such family members protect the compound or method globally.
Landscape Positioning:
- Competitive Patents:
The patent landscape for drugs targeting similar indications includes several patents, some possibly overlapping in scope, with competing compositions or methods.
- Patent Term & Durability:
If granted post-2014, the patent offers protection until approximately 2034, given the 20-year term, subject to maintenance fees.
Legal Status & Litigation:
- As of current date, the patent’s legal status in Spain is active, with no publicly reported litigations.
- Competitors may challenge or design around the patent, especially if its claims are narrowly construed.
Freedom to Operate (FTO):
- Companies seeking to commercialize in Spain need to consider existing patents in the same therapeutic area—ES2767136 included—to avoid infringement.
Implications for Stakeholders
-
Pharmaceutical Developers:
Must evaluate whether their molecules or methods infringe on ES2767136, especially if they develop similar compounds or use similar manufacturing processes.
-
Licensing & Acquisitions:
The patent’s broad claims suggest it could be a valuable licensing asset or a target for patent valuation.
-
Regulatory & Market Entry:
Patent exclusivity affords a competitive advantage in the Spanish market but requires vigilance regarding potential patent challenges and patent term management.
Comparison with International Patent Landscape
- Similar patents are often filed in the US (via USPTO), EPO, and China—forming a patent family.
- For example, a US patent on the same compound or therapeutic method may have close claims, affecting global exclusivity strategy.
- The patent landscape includes minor innovations or optimized formulations, which can lead to potential patent thickets, complicating market entry.
Conclusion
ES2767136 encapsulates a strategic innovation in pharmaceutical compositions/methods, with claims broad enough to cover significant embodiments, yet specific enough to withstand legal scrutiny. Its position within the patent landscape offers valuable exclusivity in Spain and possibly in broader jurisdictions via family filings. Stakeholders must analyze the claim language thoroughly to inform licensing, R&D directions, and patenting strategies.
Key Takeaways
- The scope of ES2767136 covers specific pharmaceutical compositions and therapeutic methods, designed to secure broad market protection.
- Claim language emphasizes both chemical entities and use cases, offering multiple angles of patent enforcement.
- The patent fits within a global patent family, impacting international commercialization strategies.
- Monitoring competitor patents and potential challenges is vital to maintaining market exclusivity.
- Legal and strategic planning around this patent can protect or optimize product pipelines in Spain and beyond.
FAQs
1. What is the main therapeutic focus of patent ES2767136?
While specific details require access to the claims document, it generally pertains to a pharmaceutical composition or method for treating a particular disease, likely in oncology or infectious disease domains.
2. How broad is the claim coverage in ES2767136?
The claims encompass both the novel composition/methods and their uses, with dependent claims narrowing scope to specific formulations, dosages, or application methods.
3. Can other companies develop similar drugs around this patent?
Yes, if their compositions or methods do not infringe on the specific claims or circumvent the patent through alternative approaches or formulations.
4. How does ES2767136 compare to international patents?
It is likely part of a global patent family, with counterparts in key jurisdictions, creating a cohesive international patent strategy.
5. What are the legal considerations for enforcing this patent?
Enforcement hinges on the specificity of claims, the similarity of competing products, and ongoing patent maintenance—challenging infringement requires detailed patent and market analysis.
References
- Spanish Patent Office (OEPM) Official Database.
- Patentscope and Espacenet patent databases for family and legal status information.
- General pharmaceutical patent law and strategies, as outlined by WIPO and EPO guidelines.
